Phenome-wide association study relating pretreatment laboratory parameters with human genetic variants in AIDS clinical trials group protocols

Open Forum Infectious Diseases

Volumn 2, Issue 1, 2015, Pages

  Moore, Carrie B ^a,b   Verma, Anurag ^b   Pendergrass, Sarah ^b   Verma, Shefali S ^b   Johnson, Daniel H ^a   Daar, Eric S ^c   Gulick, Roy M ^d   Haubrich, Richard ^e   Robbins, Gregory K ^f   Ritchie, Marylyn D ^b   Haas, David W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HARVARD UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; Clinical trials; HIV 1; Pharmacogenomics; PheWAS

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANALYTICAL PARAMETERS; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOINFORMATICS; CLINICAL PROTOCOL; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENOTYPE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; NEUTROPHIL COUNT; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHENOME WIDE ASSOCIATION STUDY; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; QUALITY CONTROL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84978328033     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu113     Document Type: Article

References (47)

1. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-79.
2. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 192:1381-6.
3. Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics 2012; 22:858-67.
4. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81:557-66.
5. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-400.
6. Kakuda T, Nijs S, Van Hoeke G. Pharmacokinetics of etravirine according to CYP2C9 and CYP2C19 metabolizer status: a meta-analysis of phase I trials. In: 20th Conference on Retroviruses and Opportunistic Infections; 2013 Feb; Atlanta, GA. (March 3-6).
7. Lubomirov R, di Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 2010; 20:217-30.
8. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011; 25:1271-80.
9. Pendergrass SA, Brown-Gentry K, Dudek S, et al. Phenome-Wide Association Study (PheWAS) for detection of pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network. PLoS Genet 2013; 9:e1003087.
10. Pendergrass SA, Brown-Gentry K, Dudek SM, et al. The use of Phenome-Wide Association Studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery. Genet Epidemiol 2011; 35:410-22.
11. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-303.
12. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-61.
13. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three-vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296:769-81.
14. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-106.
15. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-40.
16. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-56.
17. Pereyra F, Jia X, McLaren PJ, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-7.
18. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for wholegenome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-75.
19. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011. Available at: http://www.R-project.org. Accessed 1 December 2014.
20. Abecasis GR, Altshuler D, Auton A, et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467:1061-73.
21. liftOver. Available at: http://genome.ucsc.edu/cgi-bin/hgLiftOver.
22. Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. NatMethods 2013; 10:5-6.
23. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5:e1000529.
24. Verma SS, de Andrade M, Tromp G, et al. Imputation and quality control steps for combining multiple genome-wide datasets. Frontiers Genet 2014; 5:1-15.
25. Price A. EIGENSOFT. Available at: http://www.hsph.harvard.edu/alkesprice/software/.
26. Kraft P, Zeggini E, Ioannidis JPA. Replication in genome-wide association studies. Stat Sci Rev J Inst Math Stat 2009; 24:561-73.
27. Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci 2009; 106:9362-7.
28. Pendergrass SA, Frase AT, Wallace JR, et al. Genomic analyses with biofilter 2.0: knowledge driven filtering, annotation, and model development. BioData Mining 2013; 6:25.
29. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28:27-30.
30. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-5.
31. Pendergrass SA, Dudek SM, Crawford DC, et al. Synthesis-View: visualization and interpretation of SNP association results for multi-cohort, multi-phenotype data and meta-analysis. BioData Mining 2010; 3:10.
32. Wolfe D, Dudek S, Ritchie MD, et al. Visualizing genomic information across chromosomes with PhenoGram. BioData Mining 2013; 6:18.
33. Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer. http://had.co.nz/ggplot2/book. Accessed 1 December 2014.
34. Cox AJ, Ng MC, Xu J, et al. Association of SNPs in the UGT1A gene cluster with total bilirubin and mortality in the Diabetes Heart Study. Atherosclerosis 2013; 229:155-60.
35. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41:199-204.
36. Zabaneh D, Balding DJ. A genome-wide association study of the metabolic syndrome in Indian Asian men. PloS One 2010; 5:e11961.
37. Lemaitre RN, Tanaka T, TangW, et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet 2011; 7: e1002193.
38. Barber MJ, Mangravite LM, Hyde CL, et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PloS One 2010; 5:e9763.
39. Raelson JV, Little RD, Ruether A, et al. Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. Proc Natl Acad Sci USA 2007; 104: 14747-52.
40. McGovern DP, Gardet A, Törkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42:332-7.
41. Bielinski SJ, Chai HS, Pathak J, et al. Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels. Mayo Clin Proc 2011; 86:606-14.
42. Reiner AP, Lettre G, Nalls MA, et al. Genome-wide association study of white blood cell count in 16, 388 African Americans: the continental origins and genetic epidemiology network (COGENT). PLoS Genet. 2011; 7:e1002108.
43. Reich D, Nalls MA, Kao WH, et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet 2009; 5:e1000360.
44. Lettre G, Palmer CD, Young T, et al. Genome-wide association study of coronary heart disease and its risk factors in 8, 090 African Americans: the NHLBI CARe Project. PLoS Genet 2011; 7:e1001300.
45. Solovieff N, Cotsapas C, Lee PH, et al. Pleiotropy in complex traits: challenges and strategies. Nat Rev Genet 2013; 14:483-95.
46. Denny JC, Ritchie MD, Basford MA, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics 2010; 26:1205-10.
47. Di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function Pharmacogenet Genomics 2009; 19:300-9.